Human gene control by vital oncogenes: Revisiting a theoretical model and its implications for targeted cancer therapy

International Journal of Molecular Sciences

Volumn 13, Issue 1, 2012, Pages 316-335

  Willis, Rudolph E ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Carcinogenesis; Cell cycle control; Gene regulation; Gene transcription; Oncogenes; Protein kinase; Signal transduction; Steroid hormone action; Targeted cancer therapy; Transcription activator

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 4; DNA POLYMERASE; PHOSPHOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE; RETINOBLASTOMA PROTEIN; RNA POLYMERASE; STEROID RECEPTOR; TRANSCRIPTION FACTOR E2F; CYCLIN DEPENDENT KINASE; MYC PROTEIN;

ARTICLE; CANCER THERAPY; CELL CYCLE REGULATION; DEPHOSPHORYLATION; DNA METHYLATION; DNA REPLICATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MICROARRAY ANALYSIS; ONCOGENE; ONCOGENE C MYC; PROTEIN PHOSPHORYLATION; PROTEOMICS; PROTO ONCOGENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VITAL ONCOGENE; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; METABOLISM; NEOPLASMS; PATHOLOGY; THEORETICAL MODEL;

EUKARYOTA;

CYCLIN-DEPENDENT KINASES; EPIGENESIS, GENETIC; GENOME, HUMAN; HUMANS; MODELS, THEORETICAL; NEOPLASMS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENES; RETINOBLASTOMA PROTEIN;

EID: 84856301568     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13010316     Document Type: Article

References (141)

1. Britten, R.J.; Davidson, E.H. Gene regulation for higher cells: A theory. Science 1969, 165, 349-357.
2. Venters, B.J.; Pugh, B.F. How eukaryotic genes are transcribed. Crit. Rev. Biochem. Mol. Biol. 2009, 44, 117-141.
3. Rous, P. Transmission of a malignant new growth by means of a cell-free filtrate. J. Am. Med. Assoc. 1983, 250, 1445-1449.
4. Bishop, J.M. Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 1983, 52, 301-354.
5. Panganiban, A.T. Retroviral DNA integration. Cell 1985, 42, 5-6.
6. Bishop, J.M. Viral oncogenes. Cell 1985, 42, 23-38.
7. Marx, J.L. Tumor viruses and the kinase connection. Science 1981, 211, 1336-1338.
8. Erikson, R.I.; Collett, M.S.; Erikson, E.; Purchio, A.F.; Brugge, J.S. Protein phosphorylation mediated by partially purified avian sarcoma virus transforming-gene product. Cold Spring Harbor Symp. Quant. Biol. 1980, 44, 907-917.
9. Rubin, C.S.; Rosen, O.M. Protein phosphorylation. Annu. Rev. Biochem. 1975, 44, 831-887.
10. Krebs, E.G.; Beavo, J.A. Phosphorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 1979, 48, 923-959.
11. Barford, D.; Das, A.K.; Egloff, M.P. The structure and mechanism of protein phosphatases: Insights into catalysis and regulation. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 133-164.
12. Willis, R.E. Gene control by phosphoproteins: A theoretical model for eukaryotic DNA regulation. Med. Hypotheses 1984, 13, 407-437.
13. Hunter, T.; Karin, M. The regulation of transcription by phosphorylation. Cell 1992, 70, 375-387.
14. Sahyoun, N.; LeVine, H.; McConnell, R.; Bronson, D.; Cuatrecasas, P. A specific phosphoprotein phosphatase acts on histone H1 phosphorylated by protein kinase C. Proc. Natl. Acad. Sci. USA 1983, 80, 6760-6764
15. Cho, H.; Kim, T.K.; Mancebo, H.; Lane, W.S.; Flores, O.; Reinberg, D. A protein phosphatase functions to recycle RNA polymerase II. Genes Dev. 1999, 13, 1540-1552.
16. Cheng, A.; Ross, K.E.; Kaldis, P.; Solomon, M.J. Dephosphorylation of cyclin-dependent kinases by type 2C protein phosphatases. Genes Dev. 1999, 13, 2946-2957.
17. Haspel, R.L.; Darnell, J.E. A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. Proc. Natl. Acad. Sci. USA 1999, 96, 10188-10193.
18. Camps, M.; Nichols, A.; Arkinstall, S. Dual specificity phosphatases: A gene family for control of MAP kinase functions. FASEB J. 2000, 14, 6-16.
19. Janssens, V.; Goris, J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling. Biochem. J. 2001, 353, 417-439.
20. Ostman, A.; Hellberg, C.; Bohmer, F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006, 6, 307-320.
21. Owens, D.M.; Keyse, S.M. Differential regulation of MAP kinase signaling by dual-specificity protein phosphatases. Oncogene 2007, 26, 3203-3213.
22. Chitale, D.; Gong, Y.; Taylor, B.S.; Broderick, S.; Brennan, C.; Somwar, R.; Golas, B.; Wang, L.; Motoi, N.; Szoke, J. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009, 28, 2773-2783.
23. Novakofski, J. Role of proto-oncogenes in normal growth and development. J. Anim Sci. 1991, 69, 56-73.
24. Klampfer, L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 2006, 6, 107-121
25. Karin, M.; Hunter, T. Transcriptional control by protein phosphorylation: Signal transmission from the cell surface to the nucleus. Curr. Biol. 1995, 5, 747-757.
26. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4, 177-183.
27. Collins, K.; Jacks, T.; Pavletich, N.P. The cell cycle and cancer. Proc. Natl. Acad. Sci. USA 1997, 94, 2776-2778.
28. Sherr, C.J. Cancer cell cycles. Science 1996, 274, 1672-1677.
29. Park, M.T.; Lee, S.J. Cell cycle and cancer. J. Biochem. Mol. Biol. 2003, 36, 60-65.
30. Weinstein, I.B.; Joe, A.K. Mechanisms of disease: Oncogene addiction-A rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 2006, 3, 448-457.
31. Weinstein, I.B.; Joe, A. Oncogene addiction. Cancer Res. 2008, 68, 3077-3080.
32. Sharma, S.V.; Settleman, J. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21, 3214-3231.
33. Guccione, E.; Martinato, F.; Finocchiaro, G.; Luzi, L.; Tizzoni, L.; Dall'Olio, V.; Zardo, G.; Nervi, C.; Bernard, L.; Amati, B. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol. 2006, 8, 764-770.
34. Worcel, A.; Benyajati, C. Higher order coiling of DNA in chromatin. Cell 1977, 12, 83-100.
35. Felsenfeld, G. Chromatin. Nature 1978, 271, 115-122.
36. Cartwright, I.L.; Abmayr, S.M.; Fleischmann, G.; Lowenhaupt, K.; Elgin, S.C.; Keene, M.A.; Howard, G.C. Chromatin structure and gene activity: The role of nonhistone chromosomal proteins. CRC Crit. Rev. Biochem. 1982, 13, 1-86.
37. Thoma, F.; Koller, T. Unravelled nucleosomes, nucleosome beads and higher order structures of chromatin: Influence of non-histone components and histone H1. J. Mol. Biol. 1981, 149, 709-373.
38. Thoma, F.; Koller, T. Influence of histone H1 on chromatin structure. Cell 1977, 12, 101-107.
39. Berger, S.L. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 2002, 12, 142-148.
40. Berger, S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447, 407-412.
41. Dou, Y.; Mizzen, C.A.; Abrams, M.; Allis, C.D.; Gorovsky, M.A. Phosphorylation of linker histone H1 regulates gene expression in vivo by mimicking H1 removal. Mol. Cell 1999, 4, 641-347.
42. Roque, A.; Ponte, I.; Arrondo, J.L.; Suau, P. Phosphorylation of the carboxy-terminal domain of histone H1: Effects on secondary structure and DNA condensation. Nucleic Acids Res. 2008, 36, 4719-4726.
43. Baak, J.P.; Janssen, E.A.; Soreide, K.; Heikkilae, R. Genomics and proteomics-The way forward. Ann. Oncol. 2005, 16, ii30-ii44.
44. Duggan, D.J.; Bittner, M.; Chen, Y.; Meltzer, P.; Trent, J.M. Expression profiling using cDNA microarrays. Nat. Genet. 1999, 21, 10-14.
45. Trevino, V.; Falciani, F.; Barrera-Saldana, H.A. DNA microarrays: A powerful genomic tool for biomedical and clinical research. Mol. Med. 2007, 13, 527-541.
46. Schuldiner, O.; Benvenisty, N. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene 2001, 20, 4984-4994.
47. Tao, S.C.; Chen, C.S.; Zhu, H. Applications of protein microarray technology. Comb. Chem. High Througput Screen. 2007, 10, 706-718.
48. Amit, I.; Citri, A.; Shay, T.; Lu, Y.; Katz, M.; Zhang, F.; Tarcic, G.; Siwak, D.; Lahad, J.; Jacob-Hirsch, J. A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 2007, 39, 503-512.
49. Afjehi-Sadat, L.; Engidawork, E.; Felizardo-Cabatic, M.; Slavc, I.; Lubec, G. Proteomic profiling of signaling proteins in ten different tumor cell lines. Cancer Genomics 2004, 1, 427-454.
50. Manning, G.; Plowman, G.D.; Hunter, T.; Sudarsanam, S. Evolution of protein kinase signaling from yeast to man. Trends Biochem. Sci. 2002, 27, 514-520.
51. Hubbard, M.J.; Cohen, P. On target with a new mechanism for the regulation of protein phosphorylation. Trends Biochem. Sci. 1993, 18, 172-177.
52. Mann, M.; Ong, S.; Gronborg, M.; Steen, H.; Jensen, O.; Pandey, A. Analysis of protein phosphorylation using mass spectrometry: Deciphering the phosphoproteome. Trends Biotechnol. 2002, 20, 261-268.
53. Yu, L.-R.; Issaq, H.J.; Veenstra, T.D. Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets. Proteomics 2007, 1, 1042-1057.
54. Brennan, D.J.; O'Connor, D.P.; Rexhepaj, E.; Ponten, F.; Gallagher, W.M. Antibody-based proteomics: Fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer 2010, 10, 605-617.
55. Willis, R.E. Hypothesis: Is viral transformation mediated by alterations in chromosomal proteins? Med. Hypotheses 1982, 9, 517-528.
56. Whitmarsh, A.J.; Davis, R.J. Regulation of transcription factor function by phosphorylation. Cell. Mol. Life Sci. 2000, 57, 1172-1183.
57. Barberis, A.; Petrascheck, M. Transcription Activation in Eukaryotic Cells; John Wiley & Sons, Ltd: Hoboken, NJ, USA, eLS2001.
58. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428.
59. Choi, J.K.; Howe, L.J. Histone acetylation: Truth of consequences? Biochem. Cell Biol. 2009, 87, 139-150.
60. Chadee, D.N.; Taylor, W.R.; Hurta, R.A.; Allis, C.D.; Wright, J.A.; Davie, J.R. Increased phosphorylation of histone H1 in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase kinase. J. Biol. Chem. 1995, 270, 20098-20105.
61. Taylor, W.R.; Chadee, D.N.; Allis, C.D.; Wright, J.A.; Davie, J.R. Fibroblasts transformed by combinations of ras, myc and mutant p53 exhibit increased phosphorylation of histone H1 that is independent of metastatic potential. FEBS Lett. 1995, 377, 51-53.
62. Chadee, D.N.; Allis, C.D.; Wright, J.A.; Davie, J.R. Histone H1b phosphorylation is dependent upon ongoing transcription and replication in normal and ras-transformed mouse fibroblasts. J.Biol. Chem. 1997, 272, 8113-8116.
63. Dahia, P.L. PTEN, a unique tumor suppressor gene. Endocr. Related Cancer 2000, 7, 115-129.
64. Ahuja, D.; Saenz-Robles, M.T.; Pipas, J.M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005, 24, 7729-7745.
65. Sotillo, E.; Garriga, J.; Kurimchak, A.; Grana, X. Cyclin E and SV40 small T antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. J. Biol. Chem. 2008, 283, 11280-11292.
66. Watanabe, G.; Howe, A.; Lee, R.J.; Albanese, C.; Shu, I.W.; Karnezis, A.N.; Zon, L.; Kyriakis, J.; Rundell, K.; Pestell, R.G. Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc. Natl. Acad. Sci. USA 1996, 93, 12861-12866.
67. Aranda, A.; Pascual, A. Nuclear hormone receptors and gene expression. Physiol. Rev. 2001, 81, 1269-1304
68. Weigel, N.L.; Moore, N.L. Steroid receptor phosphorylation: A key modulator of multiple receptor functions. Mol. Endocrinol. 2007, 21, 2311-2319.
69. Likhite, V.S.; Stossi, F.; Kim, K.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 2006, 20, 3120-3132.
70. Bunone, G.; Briand, P.A.; Miksicek, R.J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
71. Ikeda, K.; Ogawa, S.; Tsukui, T.; Horie-Inoue, K.; Ouchi, Y.; Kato, S.; Muramatsu, M.; Inoue, S. Protein phosphatase 5 is a negative regulator of estrogen receptor-mediated transcription. Mol. Endocrinol. 2004, 18, 1131-1143.
72. Narayanan, R.; Adigun, A.A.; Edwards, D.P.; Weigel, N.L. Cyclin-dependent kinase activity is required for progesterone receptor function: Novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol. Cell. Biol. 2005, 25, 264-277.
73. Hawking, S.W. A Brief History of Time: From the Big Bang to Black Holes; Bantam Dell Publishing Group: New York, NY, USA, 1988; p. 10.
74. Garrett, D. Cell cycle control and cancer. Curr. Sci. 2001, 81, 515-521.
75. Nurse, P. A long twentieth century of the cell cycle and beyond. Cell 2000, 100, 71-78.
76. Johnson, D.G.; Walker, C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 295-312.
77. Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30, 630-641.
78. Morgan, D.O. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13, 261-291.
79. Morgan, D.O. Principles of CDK regulation. Nature 1995, 374, 131-134.
80. Kaldis, P. The cdk-activating kinase (CAK): From yeast to mammals. Cell. Mol. Life Sci. 1999, 55, 284-296.
81. Kaldis, P.; Solomon, M.J. Analysis of CAK activities from human cells. Eur. J. Biochem. FEBS 2000, 267, 4213-4221.
82. Harbour, J.W.; Luo, R.X.; Dei Santi, A.; Postigo, A.A.; Dean, D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98, 859-869.
83. Cánepa, E.T.; Scassa, M.E.; Ceruti, J.M.; Marazita, M.C.; Carcagno, A.L.; Sirkin, P.F.; Ogara, M.F. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007, 59, 419-426.
84. Massague, J. G1 cell-cycle control and cancer. Nature 2004, 432, 298-306.
85. Stamatakos, M.; Palla, V.; Karaiskos, I.; Xiromeritis, K.; Alexiou, I.; Pateras, I.; Kontzoglou, K. Cell cyclins: Triggering elements of cancer or not? World J. surg. Oncol. 2010, 8, 111:1-111:8
86. Santamaria, D.; Ortega, S. Cyclins and CDKS in development and cancer: Lessons from genetically modified mice. Front. Biosci. 2006, 11, 1164-1188.
87. Mermelshtein, A.; Gerson, A.; Walfisch, S.; Delgado, B.; Shechter-Maor, G.; Delgado, J.; Fich, A.; Gheber, L. Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br. J. Cancer 2005, 93, 338-345.
88. Deshpande, A.; Sicinski, P.; Hinds, P.W. Cyclins and cdks in development and cancer: A perspective. Oncogene 2005, 24, 2909-2915.
89. Tajara, E.H. Oral cancer and cyclins. Int. J. Oral Maxillofac. Surg. 2004, 33, 518; author reply 519.
90. Sutherland, R.L.; Musgrove, E.A. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia 2004, 9, 95-104.
91. Miehlke, S.; Yu, J.; Ebert, M.; Szokodi, D.; Vieth, M.; Kuhlisch, E.; Buchcik, R.; Schimmin, W.; Wehrmann, U.; Malfertheiner, P. Expression of G1 phase cyclins in human gastric cancer and gastric mucosa of first-degree relatives. Dig. Dis. Sci. 2002, 47, 1248-1256.
92. Bartkova, J.; Rajpert-de Meyts, E.; Skakkebaek, N.E.; Bartek, J. D-type cyclins in adult human testis and testicular cancer: Relation to cell type, proliferation, differentiation, and malignancy. J. Pathol. 1999, 187, 573-581.
93. Pines, J. Cyclins, CDKs and cancer. Semin. Cancer Biol. 1995, 6, 63-72.
94. Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81, 323-330.
95. Grana, X.; Garriga, J.; Mayol, X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 1998, 17, 3365-3383.
96. Takemura, M.; Yamamoto, T.; Kitagawa, M.; Taya, Y.; Akiyama, T.; Asahara, H.; Linn, S.; Suzuki, S.; Tamai, K.; Yoshida, S. Stimulation of DNA Polymerase [alpha] Activity by Cdk2-Phosphorylated Rb Protein. Biochem. Biophys. Res. Commun. 2001, 282, 984-990.
97. Akiyama, T.; Ohuchi, T.; Sumida, S.; Matsumoto, K.; Toyoshima, K. Phosphorylation of the retinoblastoma protein by cdk2. Proc. Natl. Acad. Sci. USA 1992, 89, 7900-7904.
98. Ewen, M.E.; Sluss, H.K.; Sherr, C.J.; Matsushime, H.; Kato, J.; Livingston, D.M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993, 73, 487-497.
99. Giacinti, C.; Giordano, A. RB and cell cycle progression. Oncogene 2006, 25, 5220-5227.
100. Chambeyron, S.; Bickmore, W.A. Chromatin Decondensation and Nuclear Reorganization of the HoxB Locus upon Induction of Transcription; Cold Spring Harbor Laboratory Press: New York, NY, USA, 2004.
101. Gilbert, N.; Thomson, I.; Boyle, S.; Allan, J.; Ramsahoye, B.; Bickmore, W.A. DNA methylation affects nuclear organization, histone modifications, and linker histone binding but not chromatin compaction. J. Cell. Biol. 2007, 177, 401-411.
102. Zheng, Y.; John, S.; Pesavento, J.J.; Schultz-Norton, J.R.; Schiltz, R.L.; Baek, S.; Nardulli, A.M.; Hager, G.L.; Kelleher, N.L.; Mizzen, C.A. Histone H1 phosphorylation is associated with transcription by RNA polymerases I and II. J. Cell. Biol. 2010, 189, 407-415.
103. Horn, P.J.; Carruthers, L.M.; Logie, C.; Hill, D.A.; Solomon, M.J.; Wade, P.A.; Imbalzano, A.N.; Hansen, J.C.; Peterson, C.L. Phosphorylation of linker histones regulates ATP-dependent chromatin remodeling enzymes. Nat. Struct. Biol. 2002, 9, 263-267.
104. Contreras, A.; Hale, T.K.; Stenoien, D.L.; Rosen, J.M.; Mancini, M.A.; Herrera, R.E. The dynamic mobility of histone H1 is regulated by cyclin/CDK phosphorylation. Mol. Cell. Biol. 2003, 23, 8626-8636.
105. Nesbit, C.; Tersak, J.; Prochownik, V. Myc oncogenes and human neoplastic disease. Oncogene 1999, 18, 3004-3016.
106. Adhikary, S.; Eilers, M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 2005, 6, 635-645.
107. Meyer, N.; Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 2008, 8, 976-990.
108. Holzel, M.; Kohlhuber, F.; Schlosser, I.; Holzel, D.; Luscher, B.; Eick, D. Myc/max/mad regulate the frequency but not the duration of productive cell cycles. EMBO Rep. 2001, 21, 1125-1132.
109. Obaya, A.J.; Mateyak, M.; Sedivy, J. Mysterious liaisons: The relationship between c-myc and the cell cycle. Oncogene 1999, 18, 2934-2941.
110. Berns, K.; Hijmanns, E.; Bernards, R. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene 1997, 15, 1347-56.
111. Fernandez, P.C.; Frank, S.R.; Wang, L.; Schroeder, M.; Liu, S.; Greene, J.; Cocito, A.; Amati, B. Genomic targets of the human c-Myc protein. Genes Dev. 2003, 17, 1115-1129.
112. Perez-Roger, I.; Solomon, D.L.; Sewing, A.; Land, H. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 1997, 14, 2373-2381.
113. Bouchard, C.; Thieke, K.; Maier, A.; Saffrich, R.; Hanley-Hyde, J.; Ansorge, W.; Reed, S.; Sicinski, P.; Bartek, J.; Eilers, M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999, 18, 5321-5333.
114. Jansen-Durr, P.; Meichle, A.; Steiner, P.; Pagano, M.; Finke, K.; Botz, J.; Wessbecher, J.; Draetta, G.; Eilers, M. Differential modulation of cyclin gene expression by MYC. Proc. Natl. Acad. Sci. USA 1993, 90, 3685-3689.
115. Hermeking, H.; Rago, C.; Schuhmacher, M.; Li, Q.; Barrett, J.F.; Obaya, A.J.; O'Connell, B.C.; Mateyak, M.K.; Tam, W.; Kohlhuber, F. Identification of CDK4 as a target of c-MYC. Proc. Natl. Acad. Sci. USA 2000, 97, 2229-2234.
116. Rustgi, A.K.; Dyson, N.; Hill, D.; Bernards, R. The c-myc oncoprotein forms a specific complex with the product of the retinoblastoma gene. Cold Spring Harbor Symp. Quant. Biol. 1991, 56, 163-167.
117. Brown, J.R.; Nigh, E.; Lee, R.J.; Ye, H.; Thompson, M.A.; Saudou, F.; Pestell, R.G.; Greenberg, M.E. Fos family members induce cell cycle entry by activating cyclin D1. Mol. Cell. Biol. 1998, 18, 5609-5619.
118. Wisdom, R.; Johnson, R.S.; Moore, C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999, 18, 188-197.
119. Haller, K.; Wu, Y.; Derow, E.; Schmitt, I.; Jeang, K.; Grassman, R. Physical interaction of human T-cell leukemia virus type 1 tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol. Cell. Biol. 2002, 22, 3327-3338.
120. Martin, N.G.; McAndrew, P.C.; Eve, P.D.; Garrett, M.D. Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases. FEBS J. 2008, 275, 3099-3109.
121. Cohen, S.; Levi-Montalcini, R. Purification and properties of a nerve growth-promoting factor isolated from mouse sarcoma 180. Cancer Res. 1957, 17, 15-20.
122. Gschwind, A.; Fischer, O.M.; Ullrich, A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 2004, 4, 361-370.
123. Ross, J.S.; Schenkein, D.P.; Pietrusko, R.; Rolfe, M.; Linette, G.P.; Stec, J.; Stagliano, N.E.; Ginsburg, G.S.; Symmans, W.F.; Pusztai, L. Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 2004, 122, 598-609.
124. Arora, A.; Scholar, E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971-979.
125. Krause, D.S.; van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Eng. J. Med. 2005, 353, 172-187.
126. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.I.; Dezube, B.J.; Jänne, P.A.; Costa, D.B. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Eng. J. Med. 2010, 363, 1693-1703.
127. Flaherty, K.T.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; O'Dwyer, P.J.; Lee, R.J.; Grippo, J.F.; Nolop, K. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Eng. J. Med. 2010, 363, 809-819.
128. Fojo, T.; Parkinson, D.R. Biologically targeted cancer therapy and marginal benefits: Are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 2010, 16, 5972-5980.
129. Darnell, J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 740-749.
130. Stadler, Z.K.; Vijai, J.; Thom, P.; Kirchhoff, T.; Hansen, N.A.; Kauff, N.D.; Robson, M.; Offit, K. Genome-wide association studies of cancer. J. Clin. Oncol. 2010, 28, 4255-4267.
131. Pusztai, L.; Ayers, M.; Stec, J.; Hortobagyi, G.N. Clinical application of cDNA microarrays in oncology. Oncologist 2003, 8, 252-258.
132. LaTulippe, E.; Satagopan, J.; Smith, A.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002, 62, 4499-4506.
133. Harada, T.; Chelala, C.; Crnogorac-Jurcevic, T.; Lemoine, N.R. Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology 2009, 9, 13-24.
134. Welsh, J.B.; Sapinoso, L.M.; Su, A.I.; Kern, S.G.; Wang-Rodriguez, J.; Moskaluk, C.A.; Frierson, H.F.; Hampton, G.M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 61, 5974-8.
135. Chen, X.; Cheung, S.T.; So, S.; Fan, S.T.; Barry, C.; Higgins, J.; Lai, K.M.; Ji, J.; Dudoit, S.; Ng, I.O.L. Gene expression patterns in human liver cancers. Mol. Biol. Cell 2002, 13, 1929-39.
136. Fehrmann, R.S.; Li, X.Y.; van der Zee, A.G.; de Jong, S.; Te Meerman, G.J.; de Vries, E.G.; Crijns, A.P. Profiling studies in ovarian cancer: A review. Oncologist 2007, 12, 960-966.
137. Sotiriou, C.; Pusztai, L. Gene-expression signatures in breast cancer. N. Eng. J. Med. 2009, 360, 790-800.
138. Chung, C.H.; Seeley, E.H.; Roder, H.; Grigorieva, J.; Tsypin, M.; Roder, J.; Burtness, B.A.; Argiris, A.; Forastiere, A.A.; Gilbert, J. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol. Biomark. Prev. 2010, 19, 358-365.
139. Chen, H.B.; Pan, K.; Tang, M.K.; Chui, Y.L.; Chen, L.; Su, Z.J.; Shen, Z.Y.; Li, E.M.; Xie, W.; Lee, K.K. Comparative proteomic analysis reveals differentially expressed proteins regulated by a potential tumor promoter, BRE, in human esophageal carcinoma cells. Biochem. Cell Biol. 2008, 86, 302-311.
140. Rush, J.; Moritz, A.; Lee, K.A.; Guo, A.; Goss, V.L.; Spek, E.J.; Zhang, H.; Zha, X.; Polakiewicz, R.D.; Comb, M.J. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotech. 2005, 23, 94-101.
141. Fan, A.C.; Deb-Basu, D.; Orban, M.W.; Gotlib, J.R.; Natkunam, Y.; O'Neill, R.; Padua, R.A.; Xu, L.; Taketa, D.; Shirer, A.E. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat. Med. 2009, 15, 566-571.